Kornimate/medical-research-clean huggingface dataset:
urinary tract infections in kidney transplant recipients

Conditions: Kidney Transplantation

Summary: the purpose of this study is to better estimate the prevalence of urinary tract infections (uti) in kidney transplant (kit) recipients, and especially multidrug resistant (mdr) bacteria. kit recipients have a higher risk of uti over the 6 first months following the transplantation. urine culture was done in a city lab or at hospital. current data on bacteriuria and candiduria lead mostly to hospital data that are incomplete..

the risk of uti after a kidney transplantation is higher than in the general population. mdr bacteria, such as extended spectrum betalactamase (esbl)-producing enterobacteriaceae or mdr pseumomoas aeruginosa are emerging threats due to antibiotic selective pressure. epidemiological data are mostly data from hospital laboratories that do not show a complete overview of the current situation. in addition, the different centers which participated to this study received before the beginning of the study a protocol to avoid carbapenem use. the main objective of this study is to assess the prevalence of mdr bacteria in an adult population of kit recipients. through this study, the management of uti in kit recipients will be improved. data on bacteria or yeasts responsible for uti (identification, resistance profile), antibiotic use, patients' outcome, and graft outcome will be collected.

Eligibility criteria:
inclusion criteria * age ≥ 18 year-old * kidney transplanted for less than 5 years * first symptomatic episode of uti with bacteria or yeast * to have a health insurance exclusion criteria * asymptomatic bacteriuria or candiduria * protected people * pregnant women -\> 2 bacteria in the urinalysis without external or internal urinary catheter

Keywords: urinary tract infection multidrug resistant bacteria candiduria epidemiology graft rejection solid organ transplantation
prevention of atrial fibrillation by optimized overdrive stimulation

Conditions: Bradycardia; Atrial Fibrillation

Summary: evaluation of dynamic atrial overdrive stimulation using the af suppression algorithm to prevent atrial tachyarrhythmias in patients with more than 2% auto mode switch episodes with optimized pacemaker programming. hypothesis: dynamic atrial overdrive (af suppression) reduces at/af burden by 30% as compared to programming dddr-(60) without af suppression when all other parameters are optimized.

atrial fibrillation is the most common heart rhythm disorder requiring therapy.

Eligibility criteria:
inclusion criteria: * indication for dual chamber pacemaker * documented paroxysmal or persistent atrial fibrillation * p-wave \>1.0 mv in sinus rhythm or sufficient detection of afib * stable antyarrhythmic therapy * age \>= 19 years * written informed consent * implantation of a identity dr 5370/5376 or later * bipolar atrial lead exclusion criteria: * permanent afib * reversible etiology of afib * hyha ii or iv * coronary artery disease with stable angina pectoris * implanted icd or planned implantation of a icd * cardiac surgery within the last 6 months or planned within 12 months * live expectancy \< 12 months * pregnancy

Keywords: pacemaker atrial fibrillation
attention training for childhood obsessive compulsive disorder: an open case series

Conditions: Obsessive Compulsive Disorder

Summary: pediatric obsessive compulsive disorder (ocd) is a chronic, impairing condition that accrues significant concurrent and long-term risk to affected youth. although empirically supported psychosocial and pharmacological treatments for ocd exist, many children and their families are not able to adequately access these treatments or derive only partial benefit from them. such findings highlight the importance of developing more effective treatment options which have the potential to be widely accessible to ocd youth. the investigators are proposing to test a computerized attention modification program, amp, in six youth with ocd in an open case series to gather information regarding protocol acceptability, feasibility and preliminary efficacy. this phase includes the development and refinement of stimuli selection procedures, behavior avoidance task, eeg protocol, and amp parameters for use with children. following ascertainment of study eligibility, participants will undergo a baseline assessment consisting of a clinical interview, neurocognitive assessments, eeg, attention bias assessment, and self report questionnaires. study participants will then receive 12 sessions of amp treatment over the course of three weeks. all youngsters and their families will be reassessed at treatment endpoint (week 4). participation will take a total of about 24 hours over the course of six weeks. participants who are treatment responders may be asked to return approximately 3 months after completing treatment for a follow-up assessment. preliminary hypotheses: 1) amp will be acceptable to youth and families and feasible to administer; 2) youth receiving amp will demonstrate decreases in threat bias and ocd symptom severity.


Eligibility criteria:
inclusion criteria: * youth ages 8 - 17 * primary dsm-iv diagnosis of ocd as determined by anxiety disorders interview schedule (adis-iv) child/parent version * child yale-brown obsessive compulsive scale (cybocs) score \> 15 * medication free or on stable medication for six weeks prior to study entry * informed parental consent and child assent. parents must agree to their child's participation in this protocol. parents will be asked to fill out self-report questionnaires and participate in assessments that will provide us with more information about their child, however parents are not considered "participants" within this protocol, as all treatment is targeted toward their child. exclusion criteria: * dsm-iv depressive disorder, bipolar disorder, ptsd, substance abuse/dependence, conduct disorder, pdd, schizophrenia, or mental retardation * concurrent psychosocial treatment for ocd * iq \< 80 * youngsters with other comorbid disorders (e.g., anxiety, adhd, odd, tic disorder) will be eligible as long as these disorders are secondary to ocd in terms of severity and impairment and do not require immediate treatment initiation.

Keywords: ocd obsessive compulsive disorder children
a trial of the may health device in transvaginal ablation of ovarian tissue under ultrasound visualization in women with pcos infertility

Conditions: Polycystic Ovary Syndrome

Summary: the objective of this study is to provide preliminary evidence for the safety and effectiveness of the may health kit in transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.


Eligibility criteria:
candidates for this study must meet all of the following criteria: inclusion criteria for female participants: 1. age: ≥ 18 to ≤ 40 years 2. diagnostic of pcos confirmed by at least 2 of 3 rotterdam criteria, defined as: 2.1 infertility associated with chronic anovulation or oligomenorrhea, defined as spontaneous intermenstrual periods of ≥35 days or a total of ≤9 menses per year 2.2 ultrasonographic evidence of pcos (ovarian volume ≥ 10ml and/or follicle number per ovary of ≥ 20) 2.3 evidence of hyperandrogenaemia: either clinical (hirsutism or acne) or biochemical (raised serum concentration of androgens (testosterone ≥ 2.5nmol/l, or fai \> 4) 3. ovarian accessibility: determined by ability to bring transvaginal ultrasound transducer into close proximity to ovaries 4. resistance to first-line pharmacological treatment, defined as at least 2 consecutive non-ovulatory cycles, including at least 1 cycle at the highest dose deemed clinically relevant for the patient 5. at least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years 6. willing to comply with protocol-specified follow-up evaluation 7. signed informed consent couple inclusion criteria: 8. normal sperm parameters based on who 2000 criteria (concentration⩾ 15 million/ml, motility a+b ⩾ 32%, normal forms ⩾ 4%). 9. ability to have regular intercourse during the study 10. no previous sterilization procedures (vasectomy, tubal ligation) that have been reversed candidates will be excluded from the study if any of the following conditions apply: 1. pregnant, parturient or breastfeeding women 2. marked obesity, bmi \> 35 3. marked hyperandrogenism (fai \> 15) 4. previous ovarian surgery: lod, endometriosis surgery, ovarian cysts surgery, patients with known or suspected periovarian adhesions. 5. subject with pacemaker, defibrillator or other active implant 6. subject is currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study 7. lack of capacity to give informed consent (individuals deprived of their liberty subject to a legal protection measure or who are unable to express their consent, individuals under guardianship or curatorship)

Keywords: anovulatory infertility
genetic analysis of hereditary non-syndromic oral clefts

Conditions: Hereditary Oral Clefts

Summary: in a collaborative effort with the ibn al-nafees hospital (damascus, syrian arab republic), individuals from multiplex families determined to have hereditary oral clefts will be studied. the purpose of this study is to identify the gene(s) involved in heritable oral clefts by linkage analysis and gene mapping strategies. characterization of genes involved in inherited oral clefts could provide important insight into the inheritance and pathogenesis of this disease.

in a collaborative effort with the ibn al-nafees hospital (damascus, syrian arab republic), individuals from multiplex families determined to have hereditary oral clefts will be studied. healthy syrian individuals with no family history of oral clefts will also be enrolled as a comparison group. the purpose of this study is to identify the gene(s) involved in heritable oral clefts by linkage analysis and gene mapping strategies. characterization of genes involved in inherited oral clefts could provide important insight into the inheritance and pathogenesis of this disease. all families are enrolled into the study by our syrian collaborators (under ethics board approval from the ibn al-nafees hospital) and only coded phenotype data and coded biospecimens are ever received at the nih.

Eligibility criteria:
* inclusion criteria: enrollment in this study will be limited to individuals with non-syndromic unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives, from families which meet the following criteria: 1. a cluster of 2 or more affected first degree relatives, such as a parent and two offspring or 2 siblings, or 2. the occurrence of oral clefts in each of 2 generations in either the proband's paternal or maternal lineages. 3. the occurrence of oral clefts in 2 or more cousins (up to second cousins) the subject population is comprised of probands and their families previously examined at the ibn-al nafees hospital or at other hospitals and clinics in the syrian arab republic as well as healthy controls from the same population. consent documents are in arabic language for non-english-speaking subjects exclusion criteria: individuals unable to provide consent, except for cases who are children and mentally impaired persons with consenting parents or guardians.

Keywords: linkage analysis genotyping birth defects family study positional cloning
effect of distraction technique on pain and anxiety during mammography

Conditions: Mammography Screening

Summary: one of the non-medical interventions aimed at reducing sensitization is the cognitive-behavioral approach, in which the individual's attention is shifted from a painful stimulus to an external stimulus. this non-pharmacological approach can be adopted to alleviate stress and reduce cortisol concentrations in response to stress. there are a limited number of studies in the literature using distraction techniques during mammography. this study will examine the effects of distraction techniques on pain and anxiety during mammography.

according to global cancer statistics worldwide, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death in women. breast cancer is the most common cancer among women in turkey (40.7%). early diagnosis of breast cancer reduces the mortality rate. mammography is one of the important diagnostic tools used in breast cancer screening. mammography is the most suitable method for screening with its easily accessible features and is the most successful imaging method in early diagnosis. the american cancer society recommends mammography for women aged 40-44. women aged 45-54 should have mammography every year for breast cancer risk. the national turkish guide recommends that screening should start at age 40 and end at age 69 and be applied every two years (özkan et al., 2016). however, studies show that most women do not routinely undergo mammography. the most important factor preventing mammography in women is defined as pain. compression of the breasts during mammography is a necessary procedure to reduce radiation dose and improve image quality. most women report experiencing pain during this compression procedure. breast tenderness before mammography, family history of breast cancer, high level of education, carelessness of healthcare personnel performing mammography, and previous pain experience with mammography increase the level of pain during mammography. although there are some techniques to relieve pain today, it is still important to find easier methods to apply. one of the non-medical interventions aimed at reducing sensitivity is the cognitive-behavioral approach; with this approach, the individual's attention is shifted from a painful stimulus to an external stimulus. this non-pharmacological approach can be adopted to alleviate stress and lower cortisol concentrations in response to stress.

Eligibility criteria:
inclusion criteria: * women aged 40-69, * those without a benign tumor in their breasts, * those without any hearing-related health problems. exclusion criteria: * women under 40 and over 69, * women with suspected breast cancer.

Keywords: mammography pain anxiety
vancomycin in the target site treatment of intracranial infection

Conditions: Vancomycin

Summary: vancomycin, a novel intravenously administered antibiotic, currently plays a key role in the management of complicated multi-organism infections. however,current lc-ms/ms methods briefly describe parameters and the only reported internal standard was sometimes difficult to obtain. in our study,an updated lc-ms/ms method for the quantitative analysis of vancomycin in human serum was developed.


Eligibility criteria:
inclusion criteria: in icu; ventricle drainage was carried out; renal function is normal, namely creatinine clearance rate is \>60ml/min; exclusion criteria: women in pregnancy or lactation;in patients with renal insufficiency, the creatinine clearance rate (clcr) is less than 60ml/min.
b-safer: branched stented anastomosis frozen elephant trunk repair

Conditions: Thoracic Aortic Aneurysm; Aortic Dissection; Congenital Aortic Anomaly

Summary: a prospective, single-center, non-blind, non-randomized safety and feasibility study of the hybrid repair of thoracic aortic pathologies requiring repair of the aortic arch proximal to the origin of innominate artery.

the proposed investigational device exemption (ide) is to assess the safety and preliminary effectiveness of the simplified hybrid frozen elephant trunk repair technique branched stented anastamosis frozen elephant trunk repair (b-safer) which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments. the study will also evaluate the device functionality when using this operative technique for device implantation including multiple components.

Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. subject is willing and able to give written informed consent to participate in the study or the subject's legally authorized representative has given written informed consent for the subject to participate in the study. 3. expected life expectancy of greater than two years after repair 4. subject has aortic pathology and requires repair or replacement of multiple damaged or diseased segments of the thoracic aorta (at least one of the following condition): thoracic aortic aneurysm considered at increased risk for rupture or complications, acute aortic dissection requiring urgent repair, congenital aortic disease requiring repair exclusion criteria: 1. subject is unfit for open surgical repair involving circulatory arrest 2. subject is comatose or suffering from irreversible severe brain malperfusion 3. subject has known sensitivity to components of the devices 4. subject has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure 5. subject is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study 6. subject has an uncorrectable bleeding anomaly 7. subject has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post- procedure 8. subject is pregnant
a multiple dose study to evaluate subcutaneous amg 108 in subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine if amg 108 in combination with methotrexate is safe and effective in the treatment of rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * subjects with active rheumatoid arthritis as diagnosed by meeting acr classification criteria for at least 6 months. * must be taking mtx consecutively for \>/= 12 weeks and at a stable dose of methotrexate at 15-25 mg weekly for at least 4 weeks prior to screening exclusion criteria: * receipt of commercial or experimental biologic therapies for the treatment of inflammatory disease * presence of serious infection * class iv rheumatoid arthritis * prior or current history of tuberculosis infection or exposure * any other dmards other than methotrexate within 6 weeks of screening * pregnant or nursing * receipt of live vaccines within 3 months * felty's syndrome

Keywords: acr criteria methotrexate dmards patient reported outcomes joint assessment
efficacy and safety study of slc022 in treating pain associated with post herpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: the purpose of this study is to evaluate the efficacy and safety of slc022 in treating pain associated with post-herpetic neuralgia (phn) in recently diagnosed patients.

this study will enroll subjects with established phn, a stable pain intensity and that meet all other eligibility criteria.

Eligibility criteria:
inclusion criteria: 1. male or female age 18 years or older. 2. a history of cutaneous herpes zoster infection and sustained pain associated with the site of the herpes zoster skin rash for \>6 months, after onset of the herpes zoster skin rash. 3. well established consistent pain during baseline phase. 4. completed a washout period of 7 days for existing pain medications. 5. evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 6. a willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. exclusion criteria: 1. pregnant or breast feeding. 2. female subjects who are not surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least one year, or are not willing to practice adequate methods of contraception if of childbearing potential. 3. previous neurolytic or neurosurgical therapy for phn. 4. treatment with local anesthetic nerve blocks within the last 30 days. 5. failure of an adequate dose of 3 or more first line drug treatments for phn-related pain due to efficacy. 6. any other type of pain which may impair the self assessment of the pain due to phn. 7. skin conditions in the affected dermatome that could alter sensation. 8. participation in other studies within 30 days before the current study begins and/or during study participation. 9. taking cyp1a2 inhibitors such as fluvoxamine, certain fluoroquinolones (e.g., ciprofloxacin, enoxacin, pefloxacin, etc), mexiletine, and zileuton. 10. history of drug or alcohol abuse during the last 5 years. 11. creatinine clearance \<50 ml/min. 12. history of malignancy other than basal cell carcinoma and carcinoma in situ. 13. history of chronic hepatitis b or c, or human immunodeficiency virus (hiv) infection. 14. clinically significant hepatic, respiratory, hematological, cardiovascular or neurological disease. 15. immunocompromised state. 16. other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Keywords: phn pain after shingles
stroke in north of norway and denmark. a prospective cohort study.

Conditions: Stroke

Summary: the study is a comparative effectiveness study with comparision of two cohorts of patients with stroke in north of norway and in denmark. at baseline information is collected from the stroke registries in both countries. time points for follow up are at 3 and 12 months post-stroke. data are collected from medical charts and with use of telephone interview in addition to self-report questionnaires. the study will provide information about functional status, health related quality of life and rehabilitation needs. information about rehabilitation services in both countries are collected and compared, and analysed in relation to patients outcome.


Eligibility criteria:
inclusion criteria: * verified stroke. admitted to stroke unit. exclusion criteria: * patients outside the regions excluded.

Keywords: rehabilitation; functional outcome